)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
Theriva Biologics (TOVX) investor relations material
Theriva Biologics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary11 Aug, 2025
Executive summary
Achieved positive topline results in the VIRAGE Phase 2b trial for VCN-01 in metastatic pancreatic cancer, meeting primary survival and safety endpoints and supporting advancement to Phase 3 planning.
VCN-01 showed promising results in a Phase 1 study for refractory retinoblastoma, with favorable safety and antitumor activity, leading to Rare Pediatric Disease and Orphan Drug designations.
Strategic focus remains on oncology, with ongoing efforts to out-license or partner legacy GI assets (SYN-004, SYN-020).
Initiated strategic outreach for potential partners and began preparing for a Phase 3 clinical trial of VCN-01.
Financial highlights
Net loss of $13.1 million for Q2 2025, compared to $8.3 million in Q2 2024; net loss per share: $(1.93) for Q2 2025.
General and administrative expenses rose to $11.2 million in Q2 2025, mainly due to a $9.2 million increase in fair value of contingent consideration tied to clinical milestones.
Research and development expenses decreased 34% year-over-year to $2.0 million in Q2 2025, reflecting lower clinical trial and manufacturing costs.
Cash and cash equivalents were $12.1 million as of June 30, 2025, with an expected cash runway into Q1 2026.
Raised $6.9 million net from a May 2025 public offering and received $1.7 million from a Spanish R&D rebate program.
Outlook and guidance
Current cash is expected to fund operations into the first quarter of 2026, covering overhead, manufacturing for near-term clinical supply, and limited research.
Additional funding is required to initiate Phase 3 trials for VCN-01 and further development of SYN-004 and SYN-020; no committed sources of future financing.
Actively pursuing equity or debt financing, partnerships, and licensing arrangements; failure to secure funding may delay or halt development programs.
Anticipates increased R&D expenses as VCN-01 advances to Phase 3 and manufacturing scale-up continues.
Expanded VIRAGE trial data to be presented at ESMO 2025 Congress in October.
VCN-01 partnership outreach focus
What drove the Q2 G&A expense surge?
Future R&D spending priorities?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Theriva Biologics earnings date
Q3 202511 Nov, 2025
LIVEat 12:00
Next Theriva Biologics earnings date
Q3 202511 Nov, 2025
LIVEat 12:00
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
)
Edge19 Sep 2025
American Express: An Empire of Plastic
How history, brand, and structure have steadily built American Express' moat, and why Warren Buffett still calls it a one-of-a-kind business.
Frequently asked questions
Theriva Biologics Inc. is a clinical-stage biotechnology company developing novel therapies for cancer and other serious diseases. The company focuses on oncolytic viruses and microbiome-based therapies designed to enhance the effectiveness of existing treatments and improve patient outcomes. Theriva’s pipeline includes investigational products targeting solid tumors, gastrointestinal diseases, and other conditions. The company is headquartered in Rockville, Maryland, and its shares are listed on the NYSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage